Volume 4.10 | Mar 15

Cord Blood News 4.10, March 15, 2012
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cord Blood News on Twitter
Immunosuppressive Function of Mesenchymal Stem Cells from Human Umbilical Cord Matrix in Immune Thrombocytopenia Patients
It was the objective of this study to assess the effect of allogeneic umbilical cord matrix/Wharton’s Jelly-derived mesenchymal stem cells on immune thrombocytopenia patients in vitro and in vivo. [Thromb Haemost] Abstract

Improve Quality Control and Regulatory Compliance. Watch the video to see how StemLab can help.
PUBLICATIONS (Ranked by Impact Factor of the Journal)

Regulation of Acute Graft-versus-Host Disease by MicroRNA-155
Here researchers show that microRNA-155 expression was up-regulated in T cells from mice developing acute graft-versus-host disease following allogeneic hematopoietic stem cell transplant. [Blood] Abstract

Studies on HOXB4 Expression During Differentiation of Human Cytomegalovirus-Infected Hematopoietic Stem Cells into Lymphocyte and Erythrocyte Progenitor Cells
Researchers investigated the role of homeobox B4 (HOXB4) mRNA/protein expression induced by human cytomegalovirus and/or all-trans retinoic acid in proliferation and committed differentiation of human cord blood hematopoietic stem cells into colony-forming-units of T-lymphocyte and erythroid progenitors in vitro. [Cell Biochem Biophys] Abstract

In Search for Cross-Reactivity to Immunophenotype Equine Mesenchymal Stromal Cells by Multicolor Flow Cytometry
Umbilical cord blood-derived undifferentiated equine mesenchymal stem cells of the fourth passage of six horses were characterized using multicolor flow cytometry based on the selected nine-marker panel of both cell surface antigens and intracytoplasmatic proteins. [Cytometry A] Abstract

Induced Transgene Expression for the Treatment of Solid Tumors by Hematopoietic Stem Cell-Based Gene Therapy
Here, researchers describe an alternative approach to treat solid tumors based on the genetic modification of hematopoietic stem and progenitor cells with lentiviral vectors. [Cancer Gene Ther] Abstract

Chromosomal Characterization of Cryopreserved Mesenchymal Stem Cells from the Human Subendothelium Umbilical Cord Vein
Researchers’ aims were to conduct a morphological, functional and chromosomal characterization of mesenchymal stem cell populations from the human subendothelium umbilical cord vein after cryopreservation. [Regen Med] Abstract

CD133 Immunomagnetic Separation: Effectiveness of the Method for CD133+ Isolation from Umbilical Cord Blood
Researchers assessed CD133 isolation in 39 umbilical cord blood samples, using a commercial immunomagnetic cell-sorting protocol, and, because of its non-reproducibility, the researchers applied optimized protocols in an effort to improve it. [Cytotherapy] Abstract

Neural Differentiation of Umbilical Cord Mesenchymal Stem Cells by Sub-Sonic Vibration
In this study, the effects of sub-sonic vibration were examined by assessing the proliferation and differentiation properties of mesenchymal stem cells. [Life Sci] Abstract

Watch The Video: Performing CFC Assays Using MethoCult™


New Biorepository Opens in Seattle to Help Uncover Mysteries of Pregnancy and Childbirth
The Global Alliance to Prevent Prematurity and Stillbirth, an initiative of Seattle Children’s, has launched an internationally accessible biorepository to advance innovative research of both normal and abnormal pregnancies, including how pregnancy affects maternal and child health after delivery. [Seattle Children’s Hospital, Research and Foundation] Press Release

Ottawa Researchers to Lead World-First Clinical Trial of Stem Cell Therapy for Septic Shock
A team of researchers from the Ottawa Hospital Research Institute and the University of Ottawa has been awarded $367,000 from the Canadian Institutes of Health Research and $75,000 from the Stem Cell Network to lead the first clinical trial in the world of a stem cell therapy for septic shock. [Ottawa Hospital Research Institute] Press Release

Alliance for Advanced Therapies to Officially Launch at BIO-Europe Spring® 2012
EBD Group announced that the Alliance for Advanced Therapies (AAT) will launch at the BIO-Europe Spring® 2012 partnering event. The ATT is a new organization devoted to supporting cell therapy, regenerative medicine and other potentially life-saving advanced therapeutics in Europe. [EBD Group AG] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW International Cord Blood Symposium – 10th Anniversary Conference: Milestones in Cord Blood Transplantation
June 7-9, 2012
San Francisco, United States

Visit our events page to see a complete list of events in the cord blood community.

Scientist – Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies, Inc.)

Business Analyst – Product Management (STEMSOFT Software, Inc.)

Postdoctoral Position – Stem Cell Research (Tsinghua University Graduate School at Shenzhen)

Stem Cell Technician (Kelly Scientific Resources)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally:
United States, Canada, Europe, Middle East to Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Cord Blood News: Archives | Events | Contact Us